

1 **Supplementary Data**

2

3 **Visualization of Type IV-A1 CRISPR-mediated repression of gene expression and** 4 **plasmid replication**

5 Mariana Sanchez-Londono^{1†}, Selina Rust^{1†}, Rogelio Hernández-Tamayo^{2,3}, José Vicente
6 Gomes-Filho¹, Martin Thanbichler^{1,2,3}, and Lennart Randau^{*1,3}

7 ¹ Department of Biology, Philipps-Universität Marburg, Marburg, Germany

8 ² Max Planck Institute for Terrestrial Microbiology, Marburg, Germany

9 ³ Center for Synthetic Microbiology (SYNMIKRO), Marburg, Germany

10 [†] These authors contributed equally

11

12 **Supplementary data content**

13 **Supplementary Table S1.** Diffusion constants of slow, intermediate, and mobile molecule populations
14 of the native Type IV-A1-mNeonGreen crRNP complex in *P. oleovorans*.

15 **Supplementary Table S2.** Mean number of molecules of the recombinant Type IV-A1 crRNP complex
16 present in the different conditions in *E. coli* BL21-AI:*dnaXmS*.

17 **Supplementary Table S3.** Diffusion constants of slow, intermediate, and mobile molecule populations
18 of the recombinant Type IV-A1-mNeonGreen crRNP complex in *E. coli* BL21-AI: *dnaXmS*.

19 **Supplementary Table S4.** Diffusion constants of slow, intermediate, and mobile molecule populations
20 of DnaX-mScarlet in *E. coli* BL21-AI:*dnaXmS* in the presence of recombinant Type IV-A1-mNeonGreen
21 crRNP complex and target/non-target plasmids.

22 **Supplementary Table S5.** Plasmids used in this study.

23 **Supplementary Table S6.** Strains used in this study.

24 **Supplementary Table S7.** Spacers used for Type IV-A1 and dCas9 CRISPRi assays.

25 **Supplementary Table S8.** Primers used for RT-qPCR.

26 **Supplementary Figure S1.** RT-qPCR of different spacers tested for dCas9-mediated CRISPRi on *hisA*
27 gene

28 **Supplementary Figure S2.** Analysis of CRISPRi transcriptome effects.

29 **Supplementary Figure S3.** Spatiotemporal dynamics of the mNeonGreen-tagged crRNPs with
30 different targets.

31 **Supplementary Figure S4.** Spatiotemporal dynamics of the DnaX-mScarlet protein in cells expressing
32 mNeonGreen-tagged crRNPs targeting or not targeting a plasmid.

33 **Supplementary Table S1.** Diffusion constants of slow, intermediate, and mobile molecule populations
 34 of the native Type IV-A1-mNeonGreen crRNP complex in *P. oleovorans*.

| Strain | cells* | tracks | D ^a | D ₁ ^b | D ₂ ^c | D ₃ ^d | F ₁ ^a | F ₂ ^b | F ₃ ^c |
|------------------------|--------|--------|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Wild type | 98 | 3614 | 0.07 ± 0.011 | 0.023 ± 0.001 | 0.128 ± 0.002 | 0.487 ± 0.002 | 33 ± 1 | 36 ± 2 | 31 ± 1 |
| Wild type + plasmid | 107 | 2350 | 0.05 ± 0.018 | 0.023 ± 0.002 | 0.128 ± 0.002 | 0.487 ± 0.001 | 2 ± 1 | 63 ± 1 | 35 ± 2 |

35 *Cells analyzed here were obtained from a total of two independent biological replicates (colonies).

36 *D_a*, MSD, average diffusion constant of all molecules (μm²·s⁻¹).

37 *D_{1b}*, diffusion constant of slow population (μm²·s⁻¹).

38 *D_{2c}*, diffusion constant of intermediate population (μm²·s⁻¹).

39 *D_{3d}*, diffusion constant of mobile population (μm²·s⁻¹).

40 *F_{1a}*, percentage of slow population (%)

41 *F_{2b}*, percentage of intermediate population (%)

42 *F_{3c}*, percentage of mobile population (%)

43

44 **Supplementary Table S2.** Mean number of molecules of the recombinant Type IV-A1 crRNP complex
 45 present in the different conditions in *E. coli* BL21-AI:*dnaXmS*.

| Strain | Mean molecules |
|--------------------|----------------|
| Genome target | 58 |
| Non-target plasmid | 75 |
| Target plasmid | 83 |

46

47 **Supplementary Table S3.** Diffusion constants of slow, intermediate, and mobile molecule populations
 48 of the recombinant Type IV-A1-mNeonGreen crRNP complex in *E. coli* BL21-AI: *dnaXmS*.

| Strain | cells* | tracks | D ^a | D ₁ ^b | D ₂ ^c | D ₃ ^d | F ₁ ^a | F ₂ ^b | F ₃ ^c |
|-----------------------|--------|--------|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Genome target | 130 | 5723 | 0.11 ± 0.018 | 0.005 ± 0.002 | 0.06 ± 0.001 | 0.42± 0.002 | 23± 2 | 66± 2 | 11± 1 |
| Non-target plasmid | 89 | 2809 | 0.14 ± 0.015 | 0.005 ± 0.001 | 0.06 ± 0.002 | 0.42 ± 0.001 | 19± 1 | 68± 2 | 13± 2 |
| Target plasmid | 97 | 3039 | 0.13 ± 0.017 | 0.005 ± 0.001 | 0.06 ± 0.001 | 0.42 ± 0.002 | 31± 2 | 58± 2 | 11± 2 |

49 *Cells analyzed here were obtained from a total of three independent biological replicates (colonies).

50 *D_a*, MSD, average diffusion constant of all molecules (μm²·s⁻¹).

51 *D_{1b}*, diffusion constant of slow population (μm²·s⁻¹).

52 *D_{2c}*, diffusion constant of intermediate population (μm²·s⁻¹).

53 *D_{3d}*, diffusion constant of mobile population (μm²·s⁻¹).

54 *F_{1a}*, percentage of slow population (%)

55 *F_{2b}*, percentage of intermediate population (%)

56 *F_{3c}*, percentage of mobile population (%)

57 **Supplementary Table S4.** Diffusion constants of slow, intermediate, and mobile molecule populations
 58 of DnaX-mScarlet in *E. coli* BL21-AI:*dnaXmS* in the presence of recombinant Type IV-A1-mNeonGreen
 59 crRNP complex and target/non-target plasmids.

| Strain | cells* | tracks | D ^a | D ₁ ^b | D ₂ ^c | D ₃ ^d | F ₁ ^a | F ₂ ^b | F ₃ ^c |
|--------------------|--------|--------|----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Non-target plasmid | 89 | 1030 | 0.02± 0.01 | 0.024 ± 0.001 | 0.11± 0.01 | 0.88± 0.01 | 4± 1 | 50± 1 | 46± 2 |
| Target plasmid | 97 | 1100 | 0.01± 0.01 | 0.024 ± 0.001 | 0.11± 0.01 | 0.88± 0.02 | 10± 1 | 81± 2 | 9± 1 |

60 *Cells analyzed here were obtained from a total of three independent biological replicates (colonies).

61 *D_a*, MSD, average diffusion constant of all molecules ($\mu\text{m}^2\cdot\text{s}^{-1}$).

62 *D_{1b}*, diffusion constant of slow population ($\mu\text{m}^2\cdot\text{s}^{-1}$).

63 *D_{2c}*, diffusion constant of intermediate population ($\mu\text{m}^2\cdot\text{s}^{-1}$).

64 *D_{3d}*, diffusion constant of mobile population ($\mu\text{m}^2\cdot\text{s}^{-1}$).

65 *F_{1a}*, percentage of slow population (%)

66 *F_{2b}*, percentage of intermediate population (%)

67 *F_{3c}*, percentage of mobile population (%)

68

Supplementary Table S5. Plasmids used in this study.

69

| Plasmid | Description | Features | Reference |
|----------------------------|--|---|-----------------------------------|
| pSIM5 | Homologous recombination vector expressing λ -Red gam, exo, and bet | Cm ^R ; Temperature sensitive origin pSC101-ts | (Kovach et al., 1995) |
| pEMG | Suicide vector used for deletions and insertions in <i>P. oleovorans</i> | Km ^R , oriT, traJ, lacZ α , oriV(R6K); | (Martínez-García & Lorenzo, 2011) |
| pMSL15 | pEMG derivative; homologous regions of <i>P. oleovorans</i> for generation of <i>P. oleovorans</i> Δ CRISPR | | This study |
| pMSL35 | pEMG derivative; homologous regions of <i>P. oleovorans</i> for generation of <i>P. oleovorans</i> Δ dinG | | This study |
| pSR58 | pEMG derivative; homologous regions and <i>sfgfp</i> with pBAD promoter for generation of <i>P. oleovorans</i> expressing sfGFP; <i>sfgfp</i> insertion site: between <i>tadA</i> and <i>mltF</i> | | This study |
| pSEVA6213S | Helper plasmid for generation of insertion and deletion strains | Gm ^R , oriV (RK2), Pem ₇ Promoter, I- <i>Scel</i> | (Wirth et al., 2020) |
| pACYCDuet TM -1 | Generation of pSR14 and pSR15 | Cm ^R , p15A ori, 2x T7 promoter, <i>lacI</i> | Novagen |
| pCDFDuet TM -1 | Generation of pMSL26 and pSR56 | Sm ^R , 2x T7 promoter, CDF origin, <i>lacI</i> | Novagen |
| pETDuet TM -1 | Generation of pMSL13 | Amp ^R , 2x T7 promoter, pBR322 origin, <i>lacI</i> | Novagen |
| pRSFDuet TM -1 | Generation of pSR77 | Km ^R , 2x P _{T7} , T7 terminator, RSF origin, <i>lacI</i> | Novagen |
| pSR77 | pRSFDuet TM -1 derivative; MCS1: Type IV-A1 CRISPR-Cas from <i>P.oleovorans</i> (<i>csf5</i> , <i>csf1</i> , <i>csf2</i> , <i>csf3</i>); MCS2: <i>csf4</i> ; repeat-spacer-repeat fragment with BseRI restriction site on the spacer. Use as Type IV-A1 negative control in the histidine auxotrophs CRISPRi assays | | This study |

| Plasmid | Description | Features | Reference |
|---------|---|----------|--------------------|
| pMSL26 | pCDFDuet™-1 derivative; MCS1: dCas9 synthetic, T7 promoter, sgRNA containing spacer and tracrRNA; BsaI restriction enzyme on spacer. Use as dCas9 negative control in the histidine auxotrophs CRISPRi assays | | This study |
| pMSL41 | pSR77 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL45 | pSR77 derivative; spacer targets <i>hisA</i> coding strand in <i>E. coli</i> BL21-AI | | This study |
| pMSL46 | pSR77 derivative; spacer targets promoter of <i>his operon</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL47 | pSR77 derivative; spacer targets internal promoter in <i>hisC</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL44 | pMSL26 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | |
| pMSL55 | pMSL26 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL56 | pMSL26 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL57 | pMSL26 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL70 | pMSL26 derivative; spacer targets <i>hisA</i> in <i>E. coli</i> BL21-AI | | This study |
| pMSL13 | pETDuet™-1 derivative; MCS1: Type IV-A1 CRISPR-Cas from <i>P. oleovorans</i> (<i>csf5</i> , <i>csf1</i> , <i>csf2</i> , <i>csf3</i>); MCS2: <i>csf4</i> ; | | This study |
| pSR56 | pCDF-Duet™-1 derivative; MCS1: Type IV-A1 repeat-spacer-repeat fragment with BseRI restriction site on the spacer. | | This study |
| pSR54 | pSR56 derivative; spacer targets <i>lacZ</i> in <i>E. coli</i> BL21-AI; for genome targeting assays using the recombinant system | | This study |
| pSR66 | pSR13 derivative; MCS1: Type IV-A1 CRISPR-Cas from <i>P. oleovorans</i> (<i>csf5</i> , <i>csf1:mNeonGreen</i> , <i>csf2</i> , <i>csf3</i>); MCS2: <i>csf4</i> ; | | This study |
| pSR24 | pSR56 derivative; spacer targets sequence on pSR14 | | |
| pSR14 | pACYCDuet™-1 derivative; MCS1: 5' AAG 3' PAM-protospacer type IV; Target plasmid in the SMM assays. | | (Guo et al., 2022) |
| pSR15 | pACYC-Duet™-1 derivative, MCS1: random 32 nt sequence; Non-target plasmid in the SMM assays. | | (Guo et al., 2022) |

| Plasmid | Description | Features | Reference |
|----------|---|--|----------------------------|
| pS448 | Generation of pMSL17. Derivative of pSEVA448 used for CRISPR-Cas9 counterselection; cured of BsaI restriction sites. | Sm ^R , oriV (pRO1600), Pm→Cas9, XylS/Pem7 promoter →sgRNA | (Wirth et al., 2020) |
| pMSL17 | pS448 derivative; sgRNA targeting Kanamycin gene from pEMG vector | | This study |
| pSEVA424 | Generation of pSR106 | Sm ^R , oriV (pRO1600), <i>lacI</i> | (Silva-Rocha et al., 2013) |
| pSR106 | pSEVA424 derivative; insertion of <i>araC</i> and Type IV-A1 repeat-spacer-repeat fragment with BseRI restriction sites in the spacer | | This study |
| pSR112 | pSR106 derivative; carrying spacer against <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR121 | pSR106 derivative; carrying spacer against promoter of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR122 | pSR106 derivative; carrying spacer against <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR124 | pSR106 derivative; carrying spacer against protospacer ~ 500 bp upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR125 | pSR106 derivative; carrying spacer against protospacer ~ 400 bp downstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR129 | pSR106 derivative; carrying spacer against protospacer ~ 2.8 kb upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR150 | pSR106 derivative; carrying spacer against protospacer ~ 900 bp upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR151 | pSR106 derivative; carrying spacer against protospacer ~ 900 bp upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR152 | pSR106 derivative; carrying spacer against protospacer ~ 800 bp downstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR153 | pSR106 derivative; carrying spacer against protospacer ~ 800 bp downstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR154 | pSR106 derivative; carrying spacer against protospacer ~ 1.6 kb upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |

| Plasmid | Description | Features | Reference |
|---------|---|----------|------------|
| pSR155 | pSR106 derivative; carrying spacer against sequence ~88 kb upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR160 | pSR106 derivative; carrying spacer against protospacer ~ 2.8 kb upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |
| pSR162 | pSR106 derivative; carrying spacer against protospacer ~ 3.8 kb upstream of mid of <i>sfgfp</i> in <i>P. oleovorans</i> | | This study |

70
71
72
73
74

Supplementary Table S6. Strains used in this study.

| Strain | Feature | Reference |
|---|---|------------------------|
| <i>Pseudomonas oleovorans</i> DSM1045 | Wild type | Leibniz Institute DSMZ |
| <i>P. oleovorans</i> DSM1045: <i>sfgfp</i> | Wild type expressing sfGFP | This study |
| <i>P. oleovorans</i> Δ <i>CRISPRarray:sfgfp</i> | Δ <i>TypeIV-A1-CRISPRarray</i> expressing sfGFP | This study |
| <i>P. oleovorans</i> Δ <i>CasDinG:sfgfp</i> | Δ <i>CasDinG</i> expressing sfGFP | This study |
| <i>Pseudomonas oleovorans:csf5mNeongreen</i> | <i>csf5-mNeongreen</i> | (Guo et al., 2022) |
| <i>E.coli</i> BL21-AI | F– ompT gal dcm lon hsdSB(rB–mB–) [malB+]K-12(λS) araB::T7RNAP-tetA | Thermo Fisher |
| BL21-AI: <i>dnaX-mS</i> | <i>dnaX-mScarlet</i> , Km ^R | This study |

75
76
77

78 **Supplementary Table S7.** Spacers used for Type IV-A1 and dCas9 CRISPRi assays.

79

| Plasmid | Description | Spacer sequence (5'-3') | Restriction recognition sites for insert |
|---------|--|-----------------------------------|--|
| pMSL26 | Negative control used in the histidine auxotrophic dCas9 CRISPRi assays | GAGACCCGAGACTGGTCTCA | Bsal |
| pMSL41 | Type IV-A1 crRNP; Protospacer is located on the non-coding strand of <i>hisA</i> ; PAM: 5'-AAG-3' | TGTTGCACCTGGTGGATCTGACCGGGGCAAAA | NA |
| pMSL44 | dCas9; Protospacer is located on the non-coding strand of <i>hisA</i> ; PAM: 5'-CGG-3'. spacer 1 | TTGCACCTGGTGGATCTGAC | NA |
| pMSL45 | Type IV-A1 crRNP; Protospacer is located on the coding strand of <i>hisA</i> ; PAM: 5'-AAG-3' | CGTGGCAGCGGGTCGTTACCGTAATCGCGTTG | NA |
| pMSL46 | Type IV-A1 crRNP; Protospacer is located in the histidine operon promoter; PAM: 5'-AAC-3' | GGTTCAGACAGGTTTAAAGAGGAATAAGAAAA | NA |
| pMSL47 | Type IV-A1 crRNP; Protospacer is located within an internal promoter of the histidine operon on <i>hisC</i> ; PAM: 5'-AAG-3' | CCTCCAGCGCAGTGTTTTAAATCTTTGTGGGAT | NA |
| pMSL55 | dCas9; Protospacer is located on the non-coding strand of <i>hisA</i> ; PAM: 5'-CGG-3'. spacer 2 | CCGGCATTAGATTTAATCGA | NA |
| pMSL56 | dCas9; Protospacer is located on the non-coding strand of <i>hisA</i> ; PAM: 5'-CGG-3'. spacer 3 | TACGGCAAACAACGCGATTA | NA |
| pMSL57 | dCas9; Protospacer is located on the non-coding strand of <i>hisA</i> ; PAM: 5'-CGG-3'. spacer 4 | GTTCCAGTGCAGGTTGGTGG | NA |
| pMSL70 | dCas9; Protospacer is located on the coding strand of <i>hisA</i> ; PAM: 5'-CGG-3' | TAATCCTGTAAGCGTGGCAG | NA |
| pSR106 | Negative control in the genomic CRISPRi assays in <i>P. oleovorans</i> strains | ATGTGACTCTCCTCCGAAGAGGAGGTAAGTAC | BseRI |

| Plasmid | Description | Spacer sequence (5'-3') | Restriction recognition sites for insert |
|---------|---|-----------------------------------|--|
| pSR112 | Type IV-A1 crRNA; Protospacer is located on the coding strand of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | GTCGATGCGACCAACGGTAAACTGACCCTGAAA | NA |
| pSR121 | Type IV-A1 crRNA; Protospacer is located on non-template strand in pBAD promoter of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | ATTAGCGGATCCTACCTGACGCTTTTTTATCGC | NA |
| pSR122 | Type IV-A1 crRNA; Protospacer is located on the coding strand of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | GCAGCCACCATCATCATCACCATTAAGCTGAA | NA |
| pSR124 | Type IV-A1 crRNA; Protospacer is located on non-template strand 115 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | TCCACATTGATTATTTGCACGGCGTCACACTT | NA |
| pSR125 | Type IV-A1 crRNA; Protospacer is located on non-template strand 58 bp downstream of end of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | GGCGGGGTTTGTCTTCTTCGGGTTTACGCTT | NA |
| pSR129 | Type IV-A1 crRNA; Protospacer is located on non-template strand 2421 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | CCAAGCGGGCTCGGGCGGCTTGTTGATGATCG | NA |
| pSR150 | Type IV-A1 crRNA; Protospacer is located on coding strand 541 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAC-3' | CCTGCAGCATGTGTGCAGGTTTGATCGTGCAT | NA |
| pSR151 | Type IV-A1 crRNA; Protospacer is located on non-coding strand 555 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAC-3' | CTGCACACATGCTGCAGGGTCCAGGGTGACG | NA |
| pSR152 | Type IV-A1 crRNA; Protospacer is located on coding strand 405 bp downstream of end of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | GCTATGTCTGAGTAACTGTTGCATATCCCTA | NA |
| pSR153 | Type IV-A1 crRNA; Protospacer is located on non-coding strand 418 bp downstream of end of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | AGGCGTTGGGGTATAGGGATATGCAACAGTTA | NA |

| Plasmid | Description | Spacer sequence (5'-3') | Restriction recognition sites for insert |
|---------|---|-----------------------------------|--|
| pSR154 | Type IV-A1 crRNA; Protospacer is located on coding strand 1183 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | TATTGGCAGATCAATGGCCAGGCCTGGGATAT | NA |
| pSR155 | Type IV-A1 crRNA; Protospacer is located on template strand 88.828 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | TAAAATCAAAGCAAAAGTTATTGCAAGATCAC | NA |
| pSR160 | Type IV-A1 crRNA; Protospacer is located on template strand 2435 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | CCGCCCGAGCCCGCTTGGCTTAGGGGATTCTGT | NA |
| pSR162 | Type IV-A1 crRNA; Protospacer is located on coding strand 3460 bp upstream of beginning of <i>sfgfp</i> inserted in <i>P. oleovorans</i> ; PAM: 5'-AAG-3' | TCGCGCTCGGCGATCATGACCGCCAGAGCCA | NA |
| pSR24 | Type IV-A1 crRNA; Protospacer is located on pSR14; 5'-AAG-3' PAM | CATCCAAGTTACGCATCAGATTTCGAGACGCGA | NA |
| pSR54 | Type IV-A1 crRNA; Protospacer is located on the coding strand of <i>lacZ</i> in BL21-AI; PAM: 5'-AAG-3' | ATCGCACTCCAGCCAGCTTCCGGCACCCTT | NA |
| pSR56 | Negative control Type IV-A1 in the genomic <i>lacZ</i> CRISPRi assays | ATGTGACTCTCCTCCGAAGAGGAGGTAAGTAC | BseRI |
| pSR77 | Negative control used in the histidine auxotrophic Type IV-A1 CRISPRi assays | ATGTGACTCTCCTCCGAAGAGGAGGTAAGTAC | BseRI |


81

Supplementary Table S8. Primers used for RT-qPCR.


82

| Oligo name | Sequence (5'-3') | Primer Efficiency Test |
|---------------------|----------------------|------------------------|
| qPCR <i>hisA</i> fw | CGTGGTACGTCTCCATCAGG | Efficiency: 93% |
| qPCR <i>hisA</i> rv | GCGGGATTTGACGTTTAGCC | R ² : 0.98 |
| qPCR <i>hisH</i> fw | CTGTTTTTACCCGGCGTTGG | Efficiency: 98% |
| qPCR <i>hisH</i> rv | CCCAGCAGTTGCATCCCTAA | R ² : 0.99 |
| qPCR <i>hisF</i> fw | AGAAGGTGCAGACGAACTGG | Efficiency: 91.6% |
| qPCR <i>hisF</i> rv | GAGACTTAATCCCACCCGCC | R ² : 0.95 |
| qPCR <i>recA</i> fw | GTTCCATGGATGTGGAAACC | Efficiency: 92% |
| qPCR <i>recA</i> rv | ATATCGACGCCAGTTTACG | R ² : 0.99 |


83




Supplementary Figure S1. RT-qPCR of different spacers tested for dCas9-mediated CRISPRi on *hisA* gene. Different spacers for the dCas9-mediated CRISPRi on target (3) were tested. RT-qPCR experiments were performed with n=3 independent colonies. A non-targeting crRNA was used as a negative control (C-). Statistical analysis was performed in comparison to C- using an unpaired two-tailed t-test. Data represent the mean (\pm SD) with * $p = 0.0114$ and *** $p = 0.0003$.



Supplementary Figure S2. Analysis of CRISPRi transcriptome effects. **A.** Agarose gel showing the result of a PCR analysis testing DNA integrity after CRISPRi assays using dCas9 or Type IV-A1. C-: Non-targeting control. Ladder: 1 kb Plus (NEB) **B.** Volcano plots showing the differential expression of genes after dCas9 treatment for the two indicated target sites. Significantly regulated genes are highlighted in salmon (downregulated) and green (upregulated). **C.** Volcano plots showing the differential expression of genes after Type IV-A1 treatment for the indicated target sites. Significantly regulated genes are highlighted in salmon (downregulated) and green (upregulated).



Supplementary Figure S3. Spatiotemporal dynamics of the mNeonGreen-tagged crRNPs with different targets. **A.** Blue-white screening after CRISPRi with mNeonGreen-tagged Type IV-A1 crRNPs targeting *lacZ*. **B.** Heat maps of the three different molecule populations for each condition. Tracks are projected onto a representative cell from each condition. Heat maps indicate the spatial distribution of mNeonGreen-tagged crRNPs heterologously expressed in *E. coli* BL21-AI. The yellow-reddish areas indicate the distribution of most of the tracks with longer scanning times. **C.** Projections of all tracks observed in three representative cells from the indicated conditions, assigned according to the diffusion coefficient to the slow (salmon), intermediate (gray), or mobile (green) population. **D.** Distribution density function of integrated spot intensities for each condition. Number of particles detected for: Genome target (58322), non-target plasmid (52987), and target plasmid (57329). In the best estimation, there are two populations of average integrated intensity for all conditions and are represented in arbitrary units (u.a). The two populations are shown as Gaussian distributions (salmon and green) and the mean number of particles is determined in the intersection point of both curves. **E.** Comparison of the Mean Square Displacement (MSD) of mNeonGreen-tagged crRNPs after different time intervals in the three conditions. Data points represent the mean MSD, with error bars indicating the standard error of the mean (SEM) (Genome target: $0.11 \pm 0.018 \mu\text{m}^2$; non-target plasmid: $0.14 \pm 0.015 \mu\text{m}^2$; target plasmid: $0.13 \pm 0.017 \mu\text{m}^2$).



Supplementary Figure S4. Spatiotemporal dynamics of the DnaX-mScarlet protein in cells expressing mNeonGreen-tagged crRNPs targeting or not targeting a plasmid. A. Three representative cells from each condition that contain projections of all tracks, assigned according to the diffusion coefficient to the slow (salmon), intermediate (gray), or mobile (green) population. **B.** Heat maps of the three different molecule populations for each condition. Tracks are projected onto a representative cell from each condition. Heat maps indicate the spatial distribution of DnaX-mScarlet in *E. coli* BL21-AI. The yellow-reddish areas indicate the distribution of most of the tracks with longer scanning times.

SUPPLEMENTARY REFERENCES

- Guo, X., Sanchez-Londono, M., Gomes-Filho, J.V., Hernandez-Tamayo, R., Rust, S., Immelmann, L.M., Schäfer, P., Wiegel, J., Graumann, P.L. and Randau, L. (2022) Characterization of the self-targeting Type IV CRISPR interference system in *Pseudomonas oleovorans*, *Nature Microbiology*, **7**, 1870–1878.
- Kovach, M.E., Elzer, P.H., Steven Hill, D., Robertson, G.T., Farris, M.A., Roop, R. and Peterson, K.M. (1995) Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes, *Gene*, **166**, 175–176.
- Martínez-García, E. and Lorenzo, V. de (2011) Engineering multiple genomic deletions in Gram-negative bacteria: analysis of the multi-resistant antibiotic profile of *Pseudomonas putida* KT2440, *Environmental microbiology*, **13**, 2702–2716.
- Silva-Rocha, R., Martínez-García, E., Calles, B., Chavarría, M., Arce-Rodríguez, A., Las Heras, A. de, Páez-Espino, A.D., Durante-Rodríguez, G., Kim, J. and Nikel, P.I. *et al.* (2013) The Standard European Vector Architecture (SEVA): a coherent platform for the analysis and deployment of complex prokaryotic phenotypes, *Nucleic Acids Research*, **41**, D666-75.